# The EBMT Cellular Therapy and Immunobiology Symposium

## From Transplantation to Gene Therapy: Cellular therapy in evolution

**November 11th-13th, 2015**

**Milano,** Italy
**San Raffaele Scientific Institute**

***Preliminary Scientific Program***

## EBMT-CTIWP BOARD

**Chairman**
**Dr. Chiara Bonini**
San Raffaele Hospital
Experimental Hematology
Milano, Italy

**Secretary**
**Prof. Christian Chabannon**
Paoli Calmettes Institute
Cell Therapy Facility
Marseille, France

## LOCAL SCIENTIFIC COMMITTEE

**Dr. Fabio Ciceri**
San Raffaele Hospital
Hematology
Milano, Italy

**Dr. Luca Vago**
San Raffaele Hospital
Hematology
Milano, Italy

**Dr. Attilio Bondanza**
San Raffaele Hospital
Hematology
Milano, Italy

**Sara Mastaglio**
San Raffaele Hospital
Hematology
Milano, Italy

## FACULTY

**Dr. Maria Ester Bernardo**
San Raffaele Hospital
Pediatric Immunohematology
Milano, Italy

**Prof. Ettore Biagi**
Milano-Bicocca University
San Gerardo Hospital
Pediatric Hematology/Oncology
Monza, Italy

**Prof. Claudio Bordignon**
Chairman & CEO
MolMed Spa
Milano, Italy

**Dr. Giulia Casorati**
San Raffaele Hospital
Experimental Immunology
Milano, Italy

**Dr. Nicoletta Cieri**
San Raffaele Hospital
Experimental Hematology Unit
Milano, Italy

**Prof. Francesco Dazzi**
King's College
Regenerative and Haematological Medicine
London, UK

**Prof. Gianpietro Dotti**
The University of North Carolina
Microbiology and Immunology
Chapel Hill, USA

**Prof. Hermann Einsele**
University Hospital
Medizinische Klinik
Würzburg, Germany

**Dr. Willem E. Fibbe**
Leiden University Medical Center
Department of Immunohematology and Bloodtransfusion
Leiden, The Netherlands

**Prof. Katharina Fleischhauer**
Essen University Hospital
Institute for experimental cellular therapy
Essen, Germany

**Dr. Maria Cristina Galli**
Istituto Superiore di Sanità
Dept. of Cell Biology and Neurosciences
Roma, Italy

**Dr. Eliane Gluckman**
Eurocord International Registry
Hospital Saint Louis
Paris, France

**Prof. Phil Greenberg**
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, USA

**Dr. Michael Hudecek**
University Hospital
Internal Medicine II
Würzburg, Germany

**Prof. Isabelle André-Schmutz**
Institut Imagine – INSERM
Paris, France

**Prof. Ulrike Köhl**
Hannover Medical School (MHH)
Institute of Cellular Therapeutics
Hannover, Germany

**Prof. Franco Locatelli**
Pediatric Hospital Bambino Gesù
Onco-Hematology
Roma, Italy

**Dr. Anna Mondino**
San Raffaele Hospital
Lymphocyte Activation
Milano, Italy

**Prof. Luigi Naldini**
San Raffaele Hospital
Tiget
Milano, Italy

**Prof. Richard O'Reilly**
Memorial Sloan Kettering Cancer Center
Department of Pediatrics
New York, USA

**Prof. Karl Peggs**
University College Hospital
Clinical Haematology
London, UK

**Prof. Alessandro Rambaldi**
Papa Giovanni XXIII Hospital
Hematology Unit
Bergamo, Italy

**Dr. Annalisa Ruggeri**
Eurocord International Registry
Hospital Saint Louis
Paris, France

**Dr. Carmen Ruiz de Elvira**
EBMT Central Registry Office
London, UK

**Prof. Jaime Sanz Caballer**
University Hospital La Fe
Hematology
Valencia, Spain

**Prof. Antoine Toubert**
Paris Diderot University
Hematology Institute
Paris, France

**Dr. Marcel R.M. van den Brink**
Memorial Sloan Kettering Cancer Center
Division of Hematologic Oncology
New York, USA

**Prof. Andrea Velardi**
University of Perugia
Hematology
Perugia, Italy

# *PRELIMINARY SCIENTIFIC PROGRAM*

## *Wednesday, November 11th 2015*

**The CTIWP Business meeting**
14:00-17:30 Agenda TBD

18:00-19:30 **Symposium Opening Lectures**

**Immune players in BMT**
*R. O'Reilly, USA*

**From bench to GMP**
*C. Bordignon, Italy*

## *Thursday, November 12th 2015*

9:00 **Keynote Lecture**

**Microbiome and GvHD**
*M. van den Brink, USA*

**Session I** **Cord Blood Transplantation: current challenges**

9:40 Do we need to collect more CBU?
*J. Sanz, Spain*

OSPEDALE
SAN RAFFAELE

| | |
|---|---|
| 10:00 | Immune reconstitution after CBT<br>*A. Ruggeri, France* |
| 10:20 | Open questions in clinical CBT<br>*E. Gluckman, France* |
| 10:40 | **Keynote Lecture** |
| | **Cellular therapy to improve outcome of haplo-HSCT**<br>*A. Velardi, Italy* |
| 11:20 | Break |
| **Session II** | **Cellular therapy to improve transplantation outcome** |
| 11:40 | MSCs: does source matter?<br>*M.E. Bernardo, Italy* |
| 12:00 | NK cell therapy in allo-SCT<br>*C. Chabannon, France* |
| 12:20 | Cellular therapy for tolerance induction: MSC vs Tregs in HSCT<br>*F. Dazzi, UK* |
| 12:40 | Cell therapy for cytomegalovirus<br>*K. Peggs, UK* |
| 13:00 | Lunch Break |
| 14:00 | Pathogen specific T cells<br>*H. Einsele, Germany* |

| | |
|---|---|
| 14:20 | Alfabeta depletion in haplo-HSCT<br>*F. Locatelli, Italy* |
| 14:40 | Targeting leukemia by lipid specific T cells<br>*G. Casorati, Italy* |
| 15:00 | **Keynote Lecture**<br>*Stored Cord Blood Units as source of cell therapy - TBC*<br>*W. Fibbe, The Netherlands* |
| 15:40 | Break |
| **Session III** | **The use of genetically redirected T cells: Improving SCT or replacing SCT?** |
| 16:00 | Targeting AML and MM with CD44v6-CAR T cells: synergy with allo-SCT?<br>*A. Bondanza, Italy* |
| 16:20 | Targeting MM with CAR T cells<br>*M. Hudecek, Germany* |
| 16:40 | CAR-T cells from lymphoid malignancies to solid tumors<br>*G. Dotti, USA* |
| 17:00 | CAR expressing NK cells<br>*U. Köhl, Germany* |
| 17:20 | **Keynote Lecture**<br>**TCR redirected T cells for myeloid leukemia**<br>*P. Greenberg, USA* |

OSPEDALE
SAN RAFFAELE

18:00 **Round table**
**Cellular Therapy: Improving the outcome of SCT or replacing SCT?**
*R. O'Reilly, G. Dotti, P. Greenberg, A. Aiuti, F. Ciceri*

## *Friday, November 13th 2015*

9:00 **Keynote Lecture**
**Lentiviral vectors and nucleases: clinical applications and future directions**
*L. Naldini, Italy*

**Session IV** **Regulation, harmonization and sustainability of cellular therapy: what can we learn from SCT?**

10:00 Cell therapy in Jacie standards
*A. Rambaldi, Italy*

10:20 A European Registry for cellular therapy
*C. Ruiz de Elvira, UK*

10:40 Coffee break

11:00 A sustainable cellular therapy approach: CAR-based CIK
*E. Biagi, Italy*

11:20 Regulatory framework from ATMP
*M.C. Galli, Italy*

| | |
|---|---|
| 11.40 | **Round Table**<br>**From HSCT to cell therapy and gene therapy: regulatory hurdles and innovative business models**<br>*M.C. Galli, M. Introna, C. Bordignon, M. Fuchs* |
| 12.45 | Lunch Break |
| **Session V** | **Cellular Therapy and allo-SCT: guidelines for patients' follow-up** |
| 13:40 | How to improve post-transplant immunological reconstitution<br>*Isabelle André-Schmutz, France* |
| 14:00 | The CTIWP studies on transplant immunobiology<br>*A. Toubert, France* |
| 14:20 | The concept of permissiveness in HSCT and cell therapy<br>*K. Fleischhauer, Germany* |
| 14:40 | Leukemia immune editing<br>*L. Vago, Italy* |
| 15:00 | Memory stem T cells in transplantation and cellular therapy<br>*N. Cieri, Italy* |
| 15.20 | **Keynote Lecture**<br>**When allogeneic hematopoietic cell transplantation meets adoptive T cell therapy**<br>*A. Mondino, Italy* |
| 16.00 | Closing remarks |

EBMT
European Society for Blood and Marrow Transplantation

# UNDER THE AUSPICES OF

GITMO
GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE

OSPEDALE
SAN RAFFAELE

# ACKNOWLEDGMENTS

NOVARTIS

SUPERSIST

medac

neovii

MACS Miltenyi Biotec

Juno THERAPEUTICS

Cell Medica

MOLMED

OSPEDALE SAN RAFFAELE